U.S. markets open in 5 hours 25 minutes
  • S&P Futures

    4,261.00
    -20.00 (-0.47%)
     
  • Dow Futures

    33,576.00
    -142.00 (-0.42%)
     
  • Nasdaq Futures

    13,515.25
    -62.50 (-0.46%)
     
  • Russell 2000 Futures

    2,005.50
    -11.40 (-0.57%)
     
  • Crude Oil

    90.38
    -1.71 (-1.86%)
     
  • Gold

    1,802.20
    -13.30 (-0.73%)
     
  • Silver

    20.51
    -0.18 (-0.88%)
     
  • EUR/USD

    1.0235
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    2.8490
    0.0000 (0.00%)
     
  • Vix

    20.87
    +0.67 (+3.32%)
     
  • GBP/USD

    1.2106
    -0.0033 (-0.27%)
     
  • USD/JPY

    133.4190
    -0.0610 (-0.05%)
     
  • BTC-USD

    24,045.42
    -813.07 (-3.27%)
     
  • CMC Crypto 200

    571.51
    +0.22 (+0.04%)
     
  • FTSE 100

    7,511.23
    +10.34 (+0.14%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Oncocyte to Announce Second Quarter 2022 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Oncocyte Corporation
Oncocyte Corporation

IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (877) 407-9716 for domestic callers or (201) 493-6779 for international callers, using conference ID: 13731553. The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.

About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.

Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.

Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com

Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
Megan.kernan@westwicke.com